Given that TRAIL combination therapies with various classes of sensitizers are being explored in preclinical and clinical trials22, 30, 36, we envision that our nontoxic, particle-based approach can act in combination with sensitizers to exert synergistic apoptotic effects on TRAIL-resistant tumour cells. The gene discussed is TNFSF10; the disease is neoplasm.